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Abstract
Background: Despite Natural Killer (NK) cells were originally defined as effectors of spontaneous cytotoxicity against
tumors, extremely limited information is so far available in humans on their capability of killing cancer cells in an autologous
setting.
Methodology/Principal Findings: We have established a series of primary melanoma cell lines from surgically resected
specimens and here showed that human melanoma cells were highly susceptible to lysis by activated autologous NK cells. A
variety of NK cell activating receptors were involved in killing: particularly, DNAM-1 and NKp46 were the most frequently
involved. Since self HLA class I molecules normally play a protective role from NK cell-mediated attack, we analyzed HLA
class I expression on melanomas in comparison to autologous lymphocytes. We found that melanoma cells presented
specific allelic losses in 50% of the patients analyzed. In addition, CD107a degranulation assays applied to NK cells
expressing a single inhibitory receptor, revealed that, even when expressed, specific HLA class I molecules are present on
melanoma cell surface in amount often insufficient to inhibit NK cell cytotoxicity. Remarkably, upon activation, also the so
called ‘‘unlicensed’’ NK cells, i.e. NK cells not expressing inhibitory receptor specific for self HLA class I molecules, acquired
the capability of efficiently killing autologous melanoma cells, thus additionally contributing to the lysis by a mechanism
independent of HLA class I expression on melanoma cells.
Conclusions/Significance: We have investigated in details the mechanisms controlling the recognition and lysis of
melanoma cells by autologous NK cells. In these autologous settings, we demonstrated an efficient in vitro killing upon NK
cell activation by mechanisms that may be related or not to abnormalities of HLA class I expression on melanoma cells.
These findings should be taken into account in the design of novel immunotherapy approaches against melanoma.
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Introduction
NK cells were initially defined on a functional basis to identify
lymphoid cells capable of lysing various tumour cell lines in the
absence of previous stimulation [1]. NK cell cytotoxic function is
regulated by numerous activating and inhibitory receptors [2] and all
available data are compatible with the concept that the ligands for
activating NK receptors are expressed primarily by ‘‘stressed’’ cells
(e.g. tumour or virus-infected cells). NKp46, NKp30 and NKp44 are
activating receptors that have been collectively named ‘‘natural
cytotoxicity receptors’’ (NCR). They represent the first activating
receptors mediating NK cytotoxicity to be identified and molecularly
characterized [3]. To date, limited information is available on the cell
surface ligands recognized by NCR with the remarkable exception of
B7 H6 ligand recognized by NKp30 [4]. A direct correlation has
been established betweenthe surface density of NCR on NK cells and
the intensity of NK-mediated cytolytic activity [5]. Another activating
receptor, NKG2D, is expressed not only by NK cells but also by
cytotoxic T lymphocytes. NKG2D recognizes the stress-inducible
MICA/B [6] and ULBPs proteins [7]. More recently, it has been
shown that DNAM-1, a triggering receptor expressed by virtually all
NK cells (that is partially expressed also by T lymphocytes and
monocytes), specifically recognizes PVR (CD155) and Nectin-2
(CD112) [8], two members of the nectin family.
With respect to the inhibitory receptors, human NK cells express
different HLA-class I-specific inhibitory receptors [2,9–11]. Important
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detect allelic determinants on HLA class I molecules. In particular,
HLA-C allotypes have either the C1 epitope (shared by HLA-Cw
alleles characterized by Ser77Asn80, including HLA-Cw1, -Cw3,
-Cw7, -Cw8, -Cw12, -Cw13, -Cw14 and -Cw16 alleles), recognized
by KIR2DL2/3, or the C2 epitope (Asn77Lys80 shared by
HLACw2, -Cw4, -Cw5, -Cw6, -Cw15, Cw*-1602, -Cw17 and
-Cw18), the ligand for KIR2DL1. Similarly, all HLA-B allotypes
have either the Bw4 or Bw6 epitope, but only the Bw4 epitope is a
ligand for KIR, its cognate inhibitory receptor being KIR3DL1
[2,9]. Another relevant receptor, CD94/NKG2A, recognizes the
nonclassical MHC class I molecule HLA-E [11]. Accordingly, NK
cells lyse target cells that have lost (or express low amounts of) MHC
class I molecules. This event occurs frequently in tumours or in
cells infected by some viruses such as certain Herpes viruses or
Adenoviruses [1,2,9]. Studies dealing with human NK cell
cytotoxicity have been almost exclusively performed employing, as
target cells, allogeneic tumour cell lines that express unrelated HLA
class I repertoires. Under these experimental conditions it is not
possible to assess whether changes in HLA class I expression in
cancer cells may indeed affect NK cell-mediated killing (due to the
possible existence of KIR-HLA class I mismatches).
Abnormalities in HLA antigen expression in malignant cells
represent a relatively frequent event in cancer biology. However,
most of the studies investigating HLA expression in cancer tissues
were performed by immunohistochemistry, a technical approach
that does not allow detection of specific HLA alleles alterations. In
addition, the use of available tumor cell lines as target cells does
not allow a comparative analysis of normal cells isolated from
the same donors. As a consequence, it is not possible to evaluate
HLA allelic losses occurred during cancer transformation. In
general, it is assumed that abnormalities in HLA expression are
extremely variable in human cancers ranging from 0 to 90% [12].
They are caused by distinct mechanisms, which include defects in
b2-microglobulin synthesis, loss of the gene(s) encoding HLA
antigen heavy chain(s), mutations which inhibit the HLA-class I
transcription or translation, defects in the regulatory mechanisms
controlling HLA antigen expression and/or abnormalities in
antigen processing [12–14].
It has long been believed that all NK cells express at least one
receptor with specificity for self-MHC class I [10,15]. This concept
was originally based on studies performed primarly on NK cell
clones and on a limited number of donors. More recently, studies
from different laboratories have shown that some NK cells may not
express any self-MHC class I-specific inhibitory receptor [16,17].
These include both NK cells expressing no inhibitory KIR or
NKG2A and NK cells that only express inhibitory KIR not
recognizing self HLA class I molecules. In humans, a substantial
fraction of normal peripheral blood (PB) NK cells (,13%) lack both
self HLA class-I specific receptors KIR and NKG2A [17].
Remarkably, these NK cells (named hereafter ‘‘HLA non-inhibited
NK’’) display low cytolytic activity even against the HLA class
I-deficient target cells K562 [17] that are highly susceptible to NK
cell-mediated lysis.However, the role andtheactivityof‘‘HLA non-
inhibited’’ (the so called ‘‘unlicensed’’) NK cells has never been
tested against autologous target cells expressing HLA class I.
To date, no substantial information exists on the ability of NK
cells to kill autologous melanomas. An efficient NK-mediated lysis
of autologous melanoma cells has been described in patients
undergoing specific T cell therapy. This reflect the selection of
melanoma variants characterized by the complete absence of
surface HLA class I due to the loss of b2-microglobulin [18]. Only
a single case of HLA class I
+ melanoma cell line was analyzed for
its susceptibility to lysis by autologous NK cells. However, these
studies were neither conclusive nor sufficiently explanatory of the
molecular mechanisms involved in lysis [19,20].
In the present study we investigated, in an autologous setting the
susceptibility to NK-mediated killing of melanomas cell lines
isolated from 10 different patients. We could detect cases with
different types of HLA class I alterations, thanks to a comparative
evaluation of autologous normal cells. In addition, the role of
different NK cell subsets and the involvement of their activating/
inhibitory receptors in the recognition and killing of human
autologous melanoma was comprehensively analyzed.
Materials and Methods
Ethics Statement
This study was approved by the Ethics Committee of the Istituto
Nazionale Ricerca sul Cancro, Genoa, where patients underwent
surgical resections of malignant melanoma lesions and received
further therapeutic treatments and follow-ups. Patients gave written
informed consent according to the Declaration of Helsinki.
Derivation of the Primary Melanoma Cell Lines
We established ten primary melanoma cell lines from patients
who underwent surgical resection of skin or lymph node metastases.
Melanoma samples were obtained immediately after surgical
resection at the Istituto Nazionale Ricerca sul Cancro (Genoa).
Briefly, fresh tumor samples were washed extensively with
phosphate-buffered saline (PBS) and were processed by mincing
the tissue with operative scissors. Mechanically dissociated tissues
underwent enzymatic digestion with 150 U/mL hyaluronidase
and 250 U/mL collagenase type IV (Sigma-Aldrich, St. Louis,
Mo). The single-cell suspension was filtered through a 100-mm cell
strainer, washed and then plated in RPMI 1640 (Lonza, Verviers,
Belgium) medium supplemented with 10% FCS (BioWhittaker,
Walkersville, MD). Effective melanoma growth was assessed using
an anti-Melanoma (MCSP)-PE mAb (Miltenyi Biotech, Bergish
Gladbach, Germany).
Primary melanoma cell lines were employed when all cultured
cells were positive for the anti-melanoma mAb (usually around the
third cell culture passage).
Purification of Fresh NK Cell Lymphocytes and
Generation of Polyclonal NK Cell Populations
Whenever available (six out of ten patients), peripheral blood
lymphocytes were derived from patient’s blood samples by centrifu-
gation on a Ficoll-Hypaque gradient. For isolation of freshly NK cells,
PBMCs were negatively selected using NK Isolation Kit (Miltenyi
Biotech, Bergish Gladbach, Germany). For generation of polyclonal
NK cell population, the highly purified magnetically selected NK cells
were cultured on irradiated feeder cells in the presence of 100 U/ml
recombinant interleukin 2 (IL-2) (Proleukin, Chiron Corp, Emeryville,
CA) and 1.5 ng/ml phytohemagglutinin (PHA) (GIBCO BRL,
Carlsbad, CA).
To obtain highly purified ‘‘HLA non-inhibited’’ NK cell subsets
from bulk NK, cells were incubated with a mixture of mAbs reactive
against KIRs recognizing HLA-I molecules of the patient and
NKG2A. Negative cells were then FACS sorted directly using
FACSAria (Becton Dickinson, Mountain View, CA) All sorted
subsets used for the experiments always displayed purity above 97%.
51Chromium Release Assay
To analyze the ability of IL-2 activated, freshly isolated and
sorted ‘‘HLA non-inhibited’’ NK cells to lyse autologous primary
cell lines, NK cells were tested in 4-h
51Chromium release tests.
Briefly, melanoma target cells were incubated with Na2
51CrO4 for
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different NK cell populations for 4 hours, either in the absence or
in the presence of various mAbs. The supernatant from the culture
was collected and the radioactivity counted and radioactivity
measured on a gamma counter (Beckman, Milan, Italy). ‘Specific’
51Cr release is calculated on the bases of the ratio{(sample release -
spontaneous release)/(total release - spontaneous release)}. Assays
were performed in triplicate at the indicated effector-target ratio.
For masking experiments, mAb of IgM isotype were used: anti-
NKp30 (F252 clone), anti-NKp44 (KS38 clone), anti-NKp46
(KL247 clone), anti-DNAM-1 (F5 clone) and anti-pan-HLA class
(A6136 clone). Masking of NKG2D was performed with BAT221
mAb, of IgG1 isotype. All antibodies cited above were produced in
our laboratory.
CD107a Assay
To investigate the surface expression of the genetically detected
HLA class I alleles and their potential inhibitory role on NK cell
functions, a CD107a degranulation assay was performed. The
autologous melanoma tumor cells were used as a target. To detect
spontaneous degranulation, a control sample without target cells
was included. An effector/target (E/T) ratio of 1.5:1 (3.75610
5
effectorcells:2610
5 targetcellsina volume of200 mL)wasused.An
AlexaFluor647-conjugated anti-CD107a (eBioscence, San Diego,
CA) was added in each well (5 mL/well) before incubation. Effectors
and targets were then coincubated at 37uC for 4 hours either in the
absence orinthe presenceoftheanti-panHLAclassI mAbA6-136;
after the first hour monensin (Sigma-Aldrich, St. Louis, MO), at a
final concentration of 2 mM, was added to inhibit cell secretion, as
previously described [21]. After 4 hours, cells were washed and
stained with a mixture of mAbs reacting with KIRs and NKG2A to
analyze the surface expression of CD107a on each single-inhibitory
receptor positive NK cell subset.
mAbs and Flow Cytometry Analysis
To characterize the surface expression of the activating receptor
ligands on the tumor cell lines, a panel of mAbs was used: anti-
MICA (clone BAM195), anti-Nectin-2 (clone L14) and anti-PVR
(clone L95) produced in our laboratory. Anti-ULBP1 (clone
M295), anti-ULBP2 (clone M310), anti-ULBP3 (clone M550) and
anti-ULBP4 (clone M475) (all from Amgen Inc., Seattle, WT). The
adhesion molecules CD54 and CD58 were detected with PE-
conjugated anti-CD54 and anti-CD58 antibodies (Beckman
Coulter, Fullerton, CA).
To evaluate surface expression of HLA-I molecules on tumor
cells and autologous PHA blasts, anti HLA class I (clone W6/32)
and anti-HLA-A2 (clone BB7.2) mAbs (both by ATCC, Manassas,
VA), anti-HLA-A1,3,11,24 (clone 131 produced in our laboratory)
and FITC-conjugated anti-HLA-Bw4 (One Lambda Inc., Canoga
Park, CA) were used. Single-inhibitory receptor positive NK cell
subsets were phenotypically isolated by the use of unlabeled mAbs
anti-NKG2A (clone Z199), anti-KIR3DL/S1/KIR3DL2 (clone
AZ158), anti-KIR2DL2/3/S2 (clone CH-L), anti-KIR3DL1/S1
(clone Z27) and anti-KIR3DL2 (clone Q66) (produced in our
laboratory) and labeled mAbs PE- and FITC-conjugated anti-
KIR2DL1/S1, PE-conjugated anti-KIR2DL2/3/S2(Miltenyi Bio-
tech, Bergish Gladbach, Germany).
For indirect immunofluorescence staining, cells were stained
with the primary mAb, followed by FITC- or PE-conjugated,
isotype-specific, goat anti-mouse or goat anti-human second
reagent (Southern Biotechnology Associated, Birmingham, AL).
Negative controls included directly labeled and unlabeled isotype-
matched irrelevant mAbs. For phenotypic analises, data were
acquired on FACSCalibur (Becton Dickinson, Mountain View,
CA). Data analysis was performed using CellQuest software
(Becton Dickinson, Mountain View, CA).
HLA Typing
To perform HLA class I serological typing, the microlympho-
cytotoxicity test was employed, according to the manufacturer’s
instruction. Lymphocytes, obtained after ACD-treated peripheral
Figure 1. Cytolitic capabilities of human NK cells against
autologous melanoma. A: Susceptibility of melanoma cells to
autologous NK cell-mediated lysis. Freshly isolated or IL-2 activated
NK cells were used as effector cells in a specific
51chromium release
assay. The effector/target (E/T) ratio used was 20:1. Four representative
patients are shown and results are expressed as means6SD derived
from experiments in triplicate. B: Flow cytometry evaluation of total
HLA class I expression (W6/32 mAb) on melanoma cells and, as a
comparison, on autologous lymphocytes. C: Susceptibility to NK-
mediated lysis of melanoma cells compared with susceptibility of HLA
class I-deficient FO-1 cell line and autologous lymphocytes stimulated
with PHA (PHA lymphocytes). Cytolitic activity was assessed by
51chromium release tests. In order to evaluate the inhibitory effect
caused by melanoma HLA class I expression on NK cell activity, lysis of
FO-1, autologous melanoma cells and PHA lymphocytes was also
analysed in the presence of the anti-pan HLA class I blocking mAb (A6-
136, IgM) at the indicated E/T ratios. At least three experiments were
performed for each patients. Representative experiments of three
patients out of six are shown. Data represent mean value6SD of
experiments performed in triplicate.
doi:10.1371/journal.pone.0008132.g001
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solution without Ca and Mg (Biotest AG, Dreieich, Germany) and
magnetic microbeads coated with anti-CD8 monoclonal antibody
(One Lambda Inc., Canoga Park, CA) were added. Cell-linked
microbeads were placed in a magnetic separator (Biotest AG,
Dreieich, Germany) and the T cell suspension obtained, was
dispensed to each well of Terasaki HLA class I 144 microplates
(Lagitre S.R.L, Milan, Italy).
To carry out genomic typing, DNA was extracted using the
QIAamp DNA blood mini kit (QIAGEN GmbH, Hilden,
Germany), according to the manufacturer’s instruction. To
identify HLA alleles, it was employed the PCR – SSO Reverse
assay using HLA Kits (Innogenetics N.V., Gent, Belgium). The
assay was performed according to the manufacturer’s instruction.
Data analysis was performed using the LIPA Interpretation
Software (Innogenetics N. V., Gent, Belgium).
To evaluate HLA-E mRNA levels on primary melanoma cell
lines total RNA was extracted using RNeasy micro kit (QIAGEN
GmbH, Hilden, Germany) according to the manufacturer’s
instruction. The cDNA synthesis was performed on about
1000 ng of RNA using oligo-dT oligonucleotides. To selectively
amplify the second and the third exons of HLA-E we used the set
of primers HLA-E up 59 ACA CCG CAC AGA TTT TCC and
HLA-E down 59 AGG GTG GCC TCA TGG TC. PCR were
performed for 30 cycles: 300 at 95uC; 300 at 56uC; and 300 at
72uC.
Statistical Analysis
Statistical analyses were performed using the Graph- Pad Prism
v. 4.00 for Windows (GraphPad Software, San Diego, Calif).
Statistical significance was evaluated by paired Student t-test.
Results and Discussion
IL-2-Activated NK Cells Effectively Kill Autologous
Melanoma Cells
We first assessed the ability of NK cells to recognize and kill
autologous primary melanoma cell lines by comparatively
analyzing the cytotoxic capabilities of freshly isolated or IL-2
activated polyclonal NK cells. These experiments (using a specific
chromium release assay) showed that NK cells require cytokine
activation for an efficient killing against autologous melanomas
while, in most cases, the lytic capabilities of unactivated NK cells
were limited (Fig. 1A).
Because autologous NK cells displayed high levels of cytolytic
activity when activated, we further investigated the level of
expression of HLA class I molecules on 10 established primary
melanoma cell lines, and, whenever possible, as a comparison, on
PHA-activated lymphocytes obtained from the same patients. We
found that HLA class I was always well expressed at the melanoma
cell surface, in some istances in amounts comparable to autologous
lymphocytes. The analyses of three representative patients out of
ten investigated are shown in figure 1B.
Next, the susceptibility of primary melanoma cell lines to NK
cell mediated lysis was compared to that of the HLA class I
negative melanoma cell line FO-1 or PHA-activated autologous
lymphocytes (Fig. 1C). In all cases, melanoma cells were efficiently
lysed by autologous NK cells even at levels similar to FO-1 cells.
On the contrary, autologous PHA blasts, were always resistant to
lysis. Pretreatment of target cells with saturating amounts of anti-
pan HLA class I mAb resulted in an increase in lysis of PHA-
blasts, while variable degrees of increases were detected in
different melanoma cell lines. As expected, addition of the anti-
HLA class I blocking mAb had no effects on the lysis of HLA-class
I-negative FO-1 cells. Remarkably, in certain melanomas, no
increase in their susceptibility to lysis was detected upon HLA class
I masking despite their high expression of (total) HLA class I on
their surface.
Taken together, these results suggest that the melanoma cells
analyzed might display defects in the expression of HLA class I
alleles interacting with inhibitory KIR expressed by autologous
NK cells.
Melanoma Cells May Display Deletions of HLA Class I
Alleles that Interact with KIR Expressed by Autologous
NK Cells
Since melanoma cells were susceptible to NK-mediated lysis
despite the high levels of (total) HLA class I expression, we
investigated whether there were deletions of HLA class I locus/
alleles specifically recognized by autologous NK cells. Notably, as
previously reported
12, selective loss of HLA class I alleles occurs
frequently in melanoma. To this end HLA class I typing was
performed in melanoma cells in comparison with autologous
peripheral blood lymphocytes. HLA class I alleles (A, B, C) were
assessed by applying both DNA-based methods and serological
typing. We also evaluated by RT-PCR the HLA-E mRNA
expression in each melanoma cell line.
These analyses revealed allele-specific deletions in half of the
primary melanoma cell lines studied. In addition, most deletions
affected alleles specifically interacting with KIRs expressed by
autologous NK cells. We found deletions at different level: some
Table 1. Comparative HLA class I typing in normal lymphocytes and melanoma cells.
HLA-A HLA-A HLA-B group HLA-B group HLA-C HLA-C
Lymphocytes Melanoma Lymphocytes Melanoma Lymphocytes Melanoma
Pt. MO A2/A29 A2/A29 Bw4/Bw6 Bw4/Bw6 Cw6/Cw16 Cw6/Cw16
Pt. CO A2/A3 XX/A3 Bw4/Bw6 XX/XX Cw4/Cw5 XX/Cw5
Pt. PA A26/A32 A26/XX Bw4/Bw6 Bw4/X Cw2/Cw4 XX/Cw4
Pt. MT A1/A25 A1/A25 Bw6/Bw6 Bw6/Bw6 Cw4/Cw7 Cw4/Cw7
Pt. OL A26/A30 A26/A30 Bw4/Bw6 Bw4/Bw6 Cw6/Cw8 Cw6/Cw8
Pt. CA A1/A1 A1/A1 Bw4/Bw6 X/Bw6 Cw4/Cw7 Cw4/X
Comprehensive HLA class I typing for each patient are shown. HLA-A,-B and -C alleles relevant for the NK cell inhibition are in bold. (X) indicates that the gene coding for
the antigen was present but the HLA protein was not expressed on the cell surface (detected by serologic typing – Terasaki method and, when possible according to
antibody availability, also by flow cytometry), whereas (XX) indicates that the gene coding for the antigen was deleted.
doi:10.1371/journal.pone.0008132.t001
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coding for the specific allele product, whereas other alleles were
present at genetic level but not detected on the cell surface. The
various defects in HLA class I allele expression detected in primary
melanoma cell cultures are summarized in Table 1.
Deletions of specific HLA class I alleles may account for the
susceptibility to NK cell mediated lysis described above. In order
to directly assess this possibility, CD107 degranulation assay was
performed in NK cells co-cultured with autologous melanoma
cells. In particular, degranulation was evaluated in NK cells
expressing single receptors specific for alleles that were either
expressed or deleted on melanoma cells. As shown in figure 2 in a
representative patient (patient CA of table 1) and described in
more details in the Material and Methods section, surface CD107a
was analyzed in NK cell subsets expressing a single receptor.
Experiments were performed (by multicolor flow cytometry) in
polyclonal NK cells after co-culture with autologous melanoma
cells, either in the presence or in the absence of anti-pan HLA class
I mAb. The degrees of degranulation were calculated by
subtracting the spontaneous degranulation occurring in the
absence of the melanoma target. Mean degranulation values
detected in each NK cell subset of six patients, upon co-culture
with autologous melanoma cells, are shown in figure 3.
In line with the data of HLA typing, NK cells expressing a single
inhibitory receptor specific for a deleted allele displayed an
efficient degranulation upon co-culture with autologus melanoma
cells (e.g. patient CO and patient CA KIR3DL1; figure 3).
Addition of anti-pan HLA class I mAb (A6-136, IgM) did not
result in any increase of cytolytic activity. In some istances, NK
cells expressing KIR specific for a deleted allele interacted with
another allele belonging to the same HLA-C specificity (e.g. in
KIR2DL1 patients CO and PA). With regard to the NKG2A
inhibitory receptor, HLA-E mRNA was detectable in all
melanoma cell lines analyzed (data not shown). However, addition
of anti-pan HLA class I blocking mAb not always increased the
degranulation of NKG2A
+ NK cell subsets during co-culture with
the related autologous melanoma cells (Figure 3). In particular, in
patients CO and CA the surface expression of HLA-E appears
virtually absent while at least decreased in patient MT. These
findings might suggest that, in agreement with previous reports
[22,23], HLA-E is often scarcely represented on melanoma cell
surface.
In contrast, in most of the NK cells expressing a single receptors
for alleles conserved in autologous melanoma cells, addition of
anti-pan HLA class I blocking mAb resulted in increases of
degranulation (Figure 3).
Expression of Low Amounts of HLA Class I Molecules May
Contribute to the NK Cell-Mediated Killing of Melanoma
Cells
Table 1 shows that, in some instances, the melanoma cells
analyzed expressed HLA class I alleles recognized by inhibitory
KIR, as revelead by specific mAbs and serological HLA typing.
Accordingly, NK cells expressing a single KIR specific for alleles
expressed by melanoma cells generally displayed low degree of
degranulation upon co-culture with autologous melanoma cells
(Figure 3). In these instances, degranulation increased in the
presence of anti-HLA class I blocking mAb. Nevertheless, in some
cases, as shown in figure 3, also NK cells expressing single
inhibitory KIR underwent degranulation despite the expression of
cognate HLA ligand on autologous melanoma cells. In patient
MT, for instance, Cw4 (i.e. the ligand of KIR2DL1) was expressed
but KIR2DL1+ NK cells could effectively degranulate, strongly
suggesting that Cw4-mediated inhibition was partially uneffective.
Addition of anti-pan HLA class I further increased degranulation
in such KIR2DL1+ NK cells. Similar results were obtained in
patient OL (for KIR3DL1+ NK cells; ligand Bw4) and in patient
CA (KIR2DL1+ NK cells; ligand Cw4). A possible explanation for
these findings might be a variable expression of HLA alleles in
melanoma cells of our primary cell lines. However, analysis of
several melanoma cell clones obtained by limiting dilutions led to
Figure 2. CD107a degranulating assay on distinct NK cell
subsets expressing single inhibitory receptors. CD107a degranu-
lating ability of activated NK cell subsets from each patient was analyzed
in the presence of autologous melanoma cells, either adding or not an
anti-pan HLA class I blocking mAb. E/T ratio=1.5:1. A representative
analysis of patient CA is shown in panel A. In order to assess the link
between HLA class I expression on melanoma cells and their
susceptibility to autologous NK cell-mediated lysis, the degranulation
of NK cell subsets, expressing a single inhibitory receptor for distinct HLA
class I molecules, was analyzed. Staining NK cells with mAbs against a
specific KIR or NKG2A and with a mixture of mAbs against the other
inhibitory receptors allowed to gate on the specific subset and evaluate
its CD107a expression after co-culture with autologous melanoma cells.
B: Melanoma specific deletion of a HLA class I allele in the same patient
CA. HLA-Bw4 was here detected by flow cytometry on the surface of
lymphocytes but not of the autologous melanoma. As a comparison,
another conserved HLA-A allele is shown. In accordance with Bw4
deletion,KIR3DL1+ NKcell subset exerts a strongcytolyticactivityagainst
autologousmelanomacells,whichis not significantlyincreasedfollowing
anti-HLA class I masking.
doi:10.1371/journal.pone.0008132.g002
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data [19], NK-mediated killing may also reflect a low expression
(and not the absence) of a given HLA-allele, that is not sufficient to
deliver a suitable inhibitory signal to NK cells.
A particular case was represented by patient CA. In this case the
inhibitory HLA ligand for KIR2DL2/3+ NK cells was lacking on
autologous melanoma target cells. However, some increase of
degranulation was detected upon HLA class I masking. A likely
explanation for this result is suggested by a recent report showing
that Cw4 (conserved on this patient melanoma cells) can bind with
low affinity KIR2DL2/3 [24].
Taken together, these data showed that: 1) HLA-E is frequently
absent on melanoma cell surface, accordingly, degranulation of
NKG2A+ NK cells was, in most cases, virtually unchanged in the
presence of anti-pan HLA I blocking mAb; 2) in the presence of
deletions of specific HLA class I alleles melanoma cells are
Figure 3. Role of HLA class I alteration in melanoma susceptibility to lysis by autologous NK cells. Summary of CD107a degranulating
assays (performed as in figure 2A) analyzed on NK cell subsets in the presence of autologous melanoma cells from six patients. Degranulation was
analyzed on (i) NK cell subsets expressing the single inhibitory receptors, (ii) NK cell subsets expressing one or more inhibitory receptors (‘‘Total HLA-
inhibited’’), (iii) NK cell subsets expressing no inhibitory receptors for self HLA (‘‘Total HLA non-inhibited’’) and (iv) the whole NK cell population. Data
represent percentages of CD107a expression in the presence of autologous target (grey columns) or in the presence of autologous target plus anti-
HLA class I mAb (black columns). Values were calculated by subtracting the spontaneous CD107a expression in the absence of the target. NK cell
subsets expressing no receptors for self-HLA are depicted on a grey background. n.d. indicates that the specific NK cell subset was not detectable in a
given patient. For each patient, on the right side of the figure, patient HLA class I antigens that are relevant for inhibiting NK cell activity are shown
and antigens that have undergone deletions on autologous melanoma cells are marked by a slash. For HLA class I A,B,C, both molecular and
serological typing were performed (see also Table 1), while HLA-E was detected only at mRNA level. For each HLA class I antigen, matched inhibitory
receptor is also specified. Results are expressed as means of 3 to 6 independent experiments. E/T ratio was 1.5:1.
doi:10.1371/journal.pone.0008132.g003
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in melanoma cell surface, specific HLA class I alleles may be
expressed in amounts insufficient to inhibit NK cells.
‘‘Unlicensed’’ NK Cells Are Efficient in Killing Autologous
Melanoma
It has recently been shown that NK cells lacking inhibitory
receptors for self MHC class I molecules are well represented in
human peripheral blood [17]. Such ‘‘HLA-non-inhibited’’ NK
cells, display a mature NK cell phenotype but are hyporesponsive
to various stimuli, including interaction with HLA class I-deficient
target cells. Indeed, because of this functional characteristics, they
have been previously termed ‘‘unlicensed’’ NK cells [16,17].
However, their possible activity against HLA-class I+ autologous
tumor cells expressing HLA class I is unknown. Notably, it has
been reported that they may improve their functional potential
upon cytokine activation [16]. Thus, we analyzed whether ‘‘HLA
non-inhibited’’ NK cells could contribute to killing of autologous
melanoma cells.
The ‘‘HLA non-inhibited’’ NK cell fraction is composed of NK
cells lacking both inhibitory KIR and NKG2A and of NK cells
that express only inhibitory KIR that do not interact with self
HLA class I molecules. A representative experiment, using a
multicolour flow cytometric assay is shown in figure 4A (patient
CA). Confirming their lack of inhibitory receptors for self HLA
class I molecules, ‘‘HLA non-inhibited’’ NK cells did not increase
their degranulation in the presence of anti-pan HLA class I
blocking mAb (Figure 4A). Surprisingly, analysis of the ‘‘HLA non-
inhibited’’ NK cell subset did not show major differences in
CD107a expression as compared to conventional (‘‘HLA-inhibit-
ed’’) NK cells when tested against autologous melanoma cells.
Indeed, levels of degranulation were similar in four out of six
patients. Only in one case (Patient CO) CD107a expression was
lower in ‘‘HLA non-inhibited’’ NK cells (Figure 3 ii, iii, iv).
The cytotoxic activity of ‘‘HLA non-inhibited’’ NK cell subsets
was also tested in a
51chromium release assay. ‘‘HLA non-
inhibited’’ NK cells were separated by sorting from ‘‘HLA-
inhibited’’ ones (as cells that were not stained by mAbs specific for
the various inhibitory receptors) ruling out possible artifacts caused
by bound antibodies. Therefore, ‘‘HLA non-inhibited’’ cells were
compared to unfractioned, unstained NK cells. As shown in
figure 4B, the three autologous melanoma cell lines tested were
lysed to the same extent by ‘‘HLA non-inhibited’’ NK cells and
unfractioned NK cells (largely represented by conventional ‘‘HLA-
inhibited’’ NK cells). Again, in contrast to ‘‘HLA inhibited’’ NK
cells, the cytotoxic activity of ‘‘HLA non-inhibited’’ was not
increased by the addition of anti-pan HLA class I blocking mAb
(Figure 4B).
Thus, although ‘‘HLA non-inhibited’’ cells had been reported to
be poorly effective in killing HLA-I negative target cells, upon IL-2
activation, they acquire both relevant degranulating capacity and
cytotoxic activity against autologous melanoma cells. Since this
NK cell subset does not express inhibitory receptors recognizing
patient HLA-class I, it is conceivable that their lower cytototoxic
potential may be compensated by the complete absence of
inhibitory signals delivered via HLA molecules. In conclusion,
‘‘HLA non-inhibited’’ (unlicensed) NK cells, if properly activated,
can effectively recognize and kill autologous tumor cells.
NK Cells Recognize and Kill Autologous Melanoma Cells
Primarly via DNAM-1 and NKp46 Activating Receptors
Further experiments were designed to analyze in ten primary
melanoma cell lines the pattern of expression of the known
Figure 4. Cytolytic activity against autologous melanoma of NK
cell subsets expressing no inhibitory receptors for self-HLA class I.
Thecytolytic activity of NK cell subsets expressing no inhibitoryreceptors
for self-HLA class I (‘‘HLA non-inhibited’’) was compared with the
counterpart expressing at least one receptor for self-HLA. A: Cytolytic
activity was assessed by CD107a degranulation assay for total ‘‘HLA-
inhibited’’andtotal‘‘HLAnon-inhibited’’ NKcellsubsets.Arepresentative
experiment is shown. Briefly, triple fluorescence staining with a mixture
of PE-conjugated anti-KIR2DL1 mAb and a mixture of other anti-KIR
(KIR2DL2/3 and KIR3DL1) and anti-NKG2A mAbs allowed to gate on the
KIR
2/NKG2A
2 subset plus NK cell subset expressing receptors for HLA
class I allelesnot expressed by the related patient.On the otherhand, the
staining permitted also to gate on all ‘‘HLA-inhibited’’ subsets. Thus, as
shown in panel A, CD107a expression of the whole ‘‘HLA non-inhibited’’
subset was analyzed and compared with that of whole ‘‘HLA-inhibited’’
subset, in the presence of absence of anti-HLA class I blocking mAb. In
agreement with the absence of inhibitory receptors for self HLA, ‘‘HLA
non-inhibited’’ NK cell subset did not increase their cytotyitc activity in
the presence of anti-HLA class I masking mAb. A summary of all
experiments performed in each patients is shown in figure 3B(ii,iii,iv) . B:
The effectiveness of ‘‘HLA non-inhibited’’ NK cell subsets in killing
autologous melanoma was also assessed by a standard
51chromium
release assay.Thewhole‘‘HLAnon-inhibited’’NKcell populations derived
by three representative patients were sorted out by flow cytometry as
double negative cells and compared with the unstained total bulk NK
populations. The comparison was performed with the unstained total NK
cells, rather than with HLA-inhibited NK cell subets, to avoid possible
interference caused by antibody binding to functional receptors. Results
shown are from three patients and data correspond to mean values6SD
of experiments performed in triplicate.
doi:10.1371/journal.pone.0008132.g004
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PLoS ONE | www.plosone.org 7 December 2009 | Volume 4 | Issue 12 | e8132Figure 5. Melanoma surface molecules and NK cell activating receptors involved in the lysis of melanoma cells by autologous NK
cells. A: Melanoma cell expression of molecules able to trigger NK cell activity. Representative data are shown for the six melanoma cell lines whose
autologous lymphocytes were also available for performing the functional experiments summarized in panel B. Melanoma cells were stained with
mAbs against ligands of NKG2D and DNAM-1 and with mAbs against adhesion molecules LFA-3 and ICAM-I. B: Contribution to the lysis by different
activating NK cell receptors. Cytotoxic activity of IL-2 activated NK cells from each patient against the autologous melanoma cells was assessed in the
presence of anti-DNAM-1, -NKp30, -NKp44, -NKp46 and -NKG2D (black columns) and isotypic control (grey column) mAbs. *: p#0.05; **: p#0.01; n.s.:
not significant. E/T ratio=20:1. Data shown represent mean values of the results obtained from three to six independent experiments.
doi:10.1371/journal.pone.0008132.g005
Melanoma Lysis by NK Cells
PLoS ONE | www.plosone.org 8 December 2009 | Volume 4 | Issue 12 | e8132DNAM-1 and NKG2D ligands. Cytofluorimetric analysis revealed
that the DNAM-1 ligands PVR and Nectin-2 were expressed by all
cell lines (PVR at a higher level than Nectin-2). Conversely, the
NKG2D ligands displayed a variable pattern of expression. Thus,
MICA was detected in five melanoma cell lines while among
ULBPs, only ULBP-3 and ULBP-4 were detectable on four and
one melanoma cell lines, respectively. Only a single melanoma cell
line was negative for all NKG2D ligands. Finally, all tumor cell
lines expressed the adhesion molecules ICAM-1 and LFA-3 with
the exception of a single melanoma cell line (patient CO) which
expressed ICAM-1 in a fraction of the cells only. Figure 5A shows
the expression pattern of these molecules in six representative
melanoma cell lines.
In parallel with the phenotypic analysis, we also evaluated the
contribution of each activating NK receptor to autologous
melanoma cell lysis. In these experiments, the NK cell cytotoxicity
was analyzed by the
51chromium release assay in the presence or
absence of blocking mAbs specific for DNAM-1, NKG2D or
NCRs to prevent the interaction between receptors and their
specific ligands on target cells. Results from six cell lines are shown
in figure 5B. In agreement with the finding that PVR and Nectin-2
were expressed by all cell lines, in all instances an efficient target
cell lysis was detected. In addition, this was significantly reduced in
the presence of anti-DNAM-1 mAbs, indicating that DNAM-1
plays a relevant role in NK-mediated lysis of melanomas.
Although to a lesser extent, also NKp46 receptor appeared
involved in the lysis, since, similar to DNAM-1, blocking this
receptor consistently reduced the lysis of all melanomas analyzed.
Conversely, NKp30 receptor was involved in the lysis of three
patients out of six. In addition, despite MICA and ULPBs were
detectable on five melanoma cell lines, only in three cases a
statistically significant reduction of the lysis could be detected upon
NKG2D blocking. However, anti-NKG2D blocking mAb consis-
tently synergized with either anti-DNAM-1 or anti-NCRs mAb in
the inhibition of NK cell cytotoxicity (not shown). Finally, blocking
of NKp44 resulted in limited decrease of cytotoxicity. Collectively,
these results suggested that the susceptibility of melanomas to NK
cell-mediated lysis is due to the expression of a variety of ligands
for activating NK receptors, in particular PVR and Nectin-2, the
DNAM-1 ligands. Although different NKG2D ligands could be
detected in some of the melanoma cell lines, this receptor appears
only partially involved in melanoma cell killing, as recently shown
also in other experimental models of melanoma [25,26].
Concluding Remarks
The molecular programme regulating NK cell activation and
killing is a complex system composed of diverse inhibitory
receptors, sensing primarly MHC-class I expression and of
activating receptors interacting with specific ligands on target
cells. In this study, by establishing primary melanoma cell lines
from different patients, we showed that melanoma cells can be
effectively killed by autologous NK cells. The mechanisms
responsible for the lysis have been analyzed in detail. We found
that the activanting receptors preferentially involved in killing were
DNAM-1 and NKp46. In some instances, killing was consequent
to specific losses on melanoma cells of HLA-I alleles recognized by
KIR expressed by autologous NK cells. In other cases, there was a
low expression of these alleles, not sufficient to deliver effective
inhibitory signals. Remarkably, we highlighted a novel mechanism
of NK cell-mediated lysis that is independent of HLA class I
expression by melanoma. Thus, tumor cell lysis could be mediated
also by the so called ‘‘unlicensed’’ NK cells, i.e. NK cells
expressing no inhibitory receptors for self HLA class I. These NK
cells are present in significant proportions in peripheral blood of
patients as well as of normal donors and may therefore play a
relevant role in killing autologous melanomas upon appropriate
activation. Our present data may suggest a more general role of
this NK cell subset in limiting and counteracting the spread of
tumor cells in vivo, particularly under conditions in which they are
activated (e.g. by IL-2). Notably, in spite of the lack of HLA-I-
specific I inhibitory receptors, their cytolytic activity is mostly
directed against tumor or otherwise stressed cells. This reflects the
expression on these cells, of the ligands of activating NK receptors,
absent or expressed in low amounts in normal cells. That this may
indeed be the case is revealed by the lack of NK-mediated GvHD
in haploidentical HSC transplantation in which ‘‘alloreactive’’ (i.e.
KIR-HLA-class I-mismatched) NK cells play a major role against
leukemic cells but do not attack normal allogeneic cells of the
recipient [27].
In conclusion, activated human NK cells are highly effective, at
least in vitro, against autologous melanoma cells via mechanisms
that may be related or not to abnormalities of HLA class I
expression in melanoma cells. However, in order to successfully
utilize NK cells in the design of novel cancer immunotherapy
approaches, it still remains mandatory to improve our knowledge
regarding the trafficking of the various NK cell subsets towards
neoplastic lesions as well as analyzing their functional properties
(and effectiveness) within human malignancies.
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